Blade Therapeutics Revenue and Competitors

Blade Therapeutics is a private biopharmaceutical company founded on a commitment to revolutionize the treatment of debilitating, incurable fibrotic diseases that impact millions of people worldwide. The Company is an expert in novel biological pathways – including autotaxin / LPA and calpain biology – that are foundational to cell and tissue damage responses leading to fibrosis. We are advancing a robust pipeline of potential first- and best-in-class investigational therapies for diseases of lung, liver and heart fibrosis, as well as neuro-degenerative diseases. This includes multiple small-molecule direct inhibitors of autotaxin / LPA and dimeric calpains that offer distinct but complementary anti-fibrotic mechanisms. Since its founding in 2015, Blade has raised approximately $90 million, including investments from Deerfield Management, MPM Capital, Pfizer Ventures, One Ventures, Osage University Partners and pharma strategic investments from Bristol-Myers Squibb and Novartis Institutes for Biomedical Research. The Company has assembled critical leadership expertise supplemented by a world-class network of scientific, pharmaceutical and clinical advisors to enable efficient and successful drug development.